Tech Company Financing Transactions
Glyscend Therapeutics Funding Round
On 6/12/2020, Glyscend Therapeutics announced $20.5 million in Series A investment from Brandon Capital Partners, Sante Ventures and private investors.
Transaction Overview
Company Name
Announced On
6/12/2020
Transaction Type
Venture Equity
Amount
$20,500,000
Round
Series A
Investors
Brandon Capital Partners (Lead Investor)
Sante Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds for the development of its novel oral polymer therapy for patients with T2D and other metabolic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1812 Ashland Ave. 110
Baltimore, MD 21205
USA
Baltimore, MD 21205
USA
Phone
Undisclosed
Website
Email Address
Overview
Glyscend, Inc. is a venture-backed biopharmaceutical company developing novel orally-delivered compounds that work on targets inside the GI tract to treat a variety of metabolic disorders, including T2D.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ashish Nimgaonkar
Chief Scientific Officer
Thomas Jozefiak
VP - Product Management
John Petersen
Browse more venture capital transactions:
Prev: 6/12/2020: Kahoot! venture capital transaction
Next: 6/12/2020: Instacart venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs